H1N1 (swine flu) & the R&D-based Pharmaceutical Industry
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
On 9 February 2026 in Geneva, IFPMA delivered a statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement.
Read moreOn 6 February 2026, IFPMA delivered a statement on Agenda item 29.1 on reform of the global health architecture at the 158th session of the WHO Executive Board in Geneva. The innovative pharmaceutical industry views this process as a critical opportunity to build a stronger, truly fit-for-purpose global health architecture. As a trusted and official...
Read moreWe appreciate the opportunity to contribute to the discussions at EB158. WHO’s work on strengthening emergency preparedness reflects a shared commitment to ensuring the world is better equipped for future health threats. We welcome this direction and the emphasis on clarity, coordination, and readiness. As EB158 documents highlight, WHO will now take on an expanded set of responsibilities...
Read more